Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
31 Januar 2024 - 7:30AM
Novo Nordisk's sales increased by 31% in Danish kroner and by 36%
at constant exchange rates to DKK 232.3 billion in 2023
Bagsværd, Denmark, 31 January 2024
- Financial report for the period 1 January 2023 to 31
December 2023
Novo Nordisk's sales increased by 31% in Danish kroner and by
36% at constant exchange rates to DKK 232.3 billion in 2023
- Operating profit increased by 37%
in Danish kroner and by 44% at constant exchange rates (CER) to DKK
102.6 billion.
- Sales in North America Operations
increased by 50% in Danish kroner (54% at CER). Sales in
International Operations increased by 11% in Danish kroner (16% at
CER).
- Sales within Diabetes and Obesity
care increased by 38% in Danish kroner to DKK 215.1 billion (42% at
CER), mainly driven by GLP-1 diabetes sales growth of 48% in Danish
kroner (52% at CER) and Obesity care growing by 147% in Danish
Kroner to DKK 41.6 billion (154% at CER). Rare disease sales
decreased by 16% measured in Danish kroner (15% at CER) reflecting
a reduction in manufacturing output.
- In January 2024, Novo Nordisk
successfully completed the first phase 3a trial with IcoSema, a
fixed-ratio once-weekly combination of basal insulin icodec and
semaglutide and a phase 1 trial with oral amycretin within Obesity
care.
- For the 2024 outlook, sales growth
is expected to be 18-26% at CER, and operating profit growth is
expected to be 21-29% at CER. Sales and operating profit growth
reported in Danish kroner is expected to be 1 and 2 percentage
points lower than at CER, respectively.
- At the Annual General Meeting on 21
March 2024, the Board of Directors will propose a final dividend of
DKK 6.40 for 2023 per share. The expected total dividend for 2023
is DKK 9.40 per share, of which DKK 3.00 was paid as interim
dividend in August 2023. The Board of Directors has decided to
initiate a new share repurchase programme of up to DKK 20
billion.
PROFIT AND LOSS |
2023 |
2022 |
Growthas reported |
Growthat CER* |
DKK million |
|
|
|
|
Net sales |
232,261 |
176,954 |
31% |
36% |
Operating
profit |
102,574 |
74,809 |
37% |
44% |
|
|
|
|
|
Net profit |
83,683 |
55,525 |
51% |
N/A |
Diluted earnings per share (in DKK) |
18.62 |
12.22 |
52% |
N/A |
* CER: Constant exchange rates (average 2022). |
|
|
|
|
Lars Fruergaard Jørgensen, president and CEO: "We are very
pleased with the strong performance in 2023 reflecting that more
than 40 million people are now benefiting from our innovative
diabetes and obesity treatments. We continue to make progress on
our strategic aspirations. Our focus in 2024 will be on reaching
more patients, progressing and expanding our pipeline as well as
the continued significant expansion of our production
capacity."
On 31 January 2024 at 13.00 CET, corresponding to 07.00 am EST,
an earnings call will be held. Investors will be able to listen in
via a link on novonordisk.com, which can be found under
‘Investors’.
About Novo NordiskNovo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat serious chronic
diseases, built upon our heritage in diabetes. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 63,400 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, X, LinkedIn and YouTube.
Financial
calendar |
|
|
7 March 2024 |
Capital Markets
Day 2024 in Copenhagen |
|
21 March
2024 |
Annual General
Meeting |
|
2 May 2024 |
Financial results
for the first three months of 2024 |
|
7 August
2024 |
Financial results
for the first half of 2024 |
|
6 November
2024 |
Financial results
for the first nine months of 2024 |
|
Novo Nordisk’s Annual Report 2022 is available
at https://www.novonordisk.com/investors/annual-report.html and
attached in iXBRL format.
Contacts
for further information |
|
Media: |
|
Ambre
James-Brown+45 3079 9289abmo@novonordisk.com |
Elizabeth
DeLuca (US)+1 609 580 9868edel@novonordisk.com |
|
|
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175dabo@novonordisk.com |
David
Heiberg Landsted+45 3077 6915dhel@novonordisk.com |
Jacob Martin
Wiborg Rode+45 3075 5956jrde@novonordisk.com |
Mark Joseph
Root (US)+1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer+45 3075 6656azey@novonordisk.com |
Frederik
Taylor Pitter+45 3075 8259fptr@novonordisk.com |
Company announcement No 7 / 2024
- PR240131-Full-year-2023
- NOVO-2023-12-31-en
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024